Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Orchid Chemicals & Pharmaceuticals Articles

New European anti-infectives company, Allecra Therapeutics, created

18 April 2013

News briefs from Genzyme, Sagent, Orchid and Kyowa Hakko

14 November 2012

Hospira to acquire Orchid API production and R&D facility

30 August 2012

As US District Court dismisses patent use code counterclaim, all eyes move to the Supreme Court Prandin case, says law firm

22 November 2011

India’s Orchid buys US drugmaker Karalex; completes deal with Hospira

11 June 2010

Hospira to buy Orchid's generic injectable business for $400 million

16 December 2009

India's Orchid buys out rest of Bexel

14 August 2006

Alpharma in deal with India's Orchid

7 March 2005

India's Orchid to buy Mano Pharma

6 January 2003

India's Orchid sets up JV in China

28 January 2002

Orchid of India shelves plans for factory

20 January 2000

Orchid looks for more foreign investment

2 September 1999

Orchid looking to attract more foreign investment

20 August 1999

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS